Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

Launched by DUKE UNIVERSITY · Oct 6, 2010

Keywords

ClinConnect Summary

A variety of trials of immunotherapy in metastatic melanoma have clearly demonstrated that immune responses against melanoma can be induced, but only a few patient have responded clinically, suggesting that new strategies to enhance anti-cancer immune responses are needed. Most of these immunotherapy trials have focused on antigen delivery and providing stimulatory antigen-specific signals to T cells. However, the induction of antigen-specific T cell-mediated immune responses is regulated not only by stimulatory signals, but also by inhibitory receptor-mediated signals. Studies have demonst...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with confirmed metastatic melanoma
• • Karnofsky performance status greater than or equal to 70%.
• • Estimated life expectancy \> 6 months.
• • Age \> 17 years.
• * Adequate hematologic function with:
• • WBC \>= 3000 mm3
• • hemoglobin \>= 9 mg/dl
• • platelets \>= 100,000/mm3
• * Adequate renal and hepatic function with:
• • serum creatinine \< 2.5 mg/dl
• • bilirubin \< 2.0 mg/dl
• • AST/SGOT \< 70 U/L
• • ALT/SGPT \< 70 U/L
• • Alkaline Phosphatase ≤ 135 U/L
• • Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
• • Ability to return to Duke University Medical Center for adequate follow-up as required by this protocol.
• Exclusion Criteria:
• • Subjects undergoing concurrent chemotherapy, radiation therapy, or immunotherapy will be excluded.
• • The subject has previously irradiated, surgically treated, or newly diagnosed central nervous system (CNS) metastases will be excluded (Pre-enrollment head CT is not required if not indicated by clinical signs or symptoms).
• • Subjects with a history of autoimmune disease such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis will be excluded.
• • Subjects with serious concurrent chronic or acute illness such as pulmonary (asthma or COPD), cardiac (NYHA class III or IV) or hepatic disease, or other illness considered by the principal investigator to constitute an unwarranted high risk for investigational drug administration will be excluded.
• • Subjects with medical or psychological impediment to probable compliance with the protocol will be excluded.
• • Subjects with concurrent second malignancy other than melanoma or non-melanoma skin cancer will be excluded. In the event of prior non-melanoma malignancies treated surgically, the subject must be considered NED (no evidence of disease) for a minimum of 3 years prior to enrollment.
• • Presence of an active acute or chronic infection, including symptomatic urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot) or viral hepatitis (as determined by HBsAg and Hepatitis C serology) will lead to subject exclusion.
• • Subjects receiving steroid therapy (or other immunosuppressive agents such as azathioprine or cyclosporine A) are excluded on the basis of potential immune suppression.
• • Subjects with inadequate peripheral vein access to undergo leukapheresis will be excluded.
• • Female subjects with a positive pregnancy test, as well as those who have not previously undergone hysterectomy and/or bilateral oophorectomy and are unwilling to utilize a medically approved form of contraception, from the time of enrollment until 6 weeks after the final immunization, will be excluded.
• • Male subjects, not previously surgically sterilized, who are unwilling to use a condom with spermicide during any sexual activity occurring over the entire immunization period and for the 6 weeks that immediately follow the final immunization will be excluded.
• • Subjects with a documented history of severe allergic reaction to beta-lactams, eggs or soy products.